Intuniv Shortage: What Providers and Prescribers Need to Know in 2026

For prescribers across pediatrics, psychiatry, and primary care, Intuniv (guanfacine extended-release) has become an increasingly important tool in ADHD management — particularly as an alternative or adjunct to stimulant medications during the ongoing stimulant shortage. This clinical briefing summarizes what you need to know about Intuniv availability in 2026, prescribing implications during stocking gaps, and practical tools to help your patients access their medication.

Current U.S. Availability Status

As of early 2026, Intuniv (guanfacine ER) is not listed on the FDA's Drug Shortage database for the U.S. market. Because guanfacine ER is not a controlled substance, it is not subject to DEA aggregate production quotas — the primary mechanism that has created formal national shortages of Schedule II stimulants since 2022.

However, patient-reported pharmacy stockouts remain a clinical reality. Several concurrent factors are driving this:

• Demand displacement from stimulant shortages: Both Adderall (amphetamine mixed salts) and methylphenidate remain on the FDA shortage list in 2026. The resulting prescribing shift toward non-stimulants has increased demand for Intuniv substantially.
• Adjunct prescribing patterns: Guanfacine ER is increasingly used concurrently with stimulants to augment efficacy and reduce stimulant-related side effects (particularly irritability, rebound, and sleep disruption), further increasing aggregate demand.
• Generic market segmentation: Multiple manufacturers produce generic guanfacine ER, but individual pharmacies typically stock only one brand. Manufacturer-level backorders can create pharmacy-level stockouts even when other generics are nationally available.

Critical Safety Concern: Abrupt Discontinuation

This is the most important clinical point for providers to communicate to patients and families during any supply disruption:

Guanfacine ER must not be stopped abruptly. Abrupt discontinuation is associated with rebound hypertension, tachycardia, and increased anxiety. This is particularly concerning in pediatric patients who may not reliably report cardiovascular symptoms.

Recommended discontinuation protocol when medication is unavailable:

1. Reduce dose by no more than 1 mg per week
2. Monitor blood pressure and heart rate at each step
3. If abrupt discontinuation cannot be avoided (e.g., immediate stockout), monitor BP and HR at 48 hours and day 4; continue weekly monitoring if BP remains elevated

Prescribing Considerations During Stocking Gaps

When your patient cannot fill a specific strength at their usual pharmacy, consider the following clinical options:

• Different pharmacy search: Independent pharmacies often carry different generic manufacturers than chain pharmacies. Direct patient to call several pharmacies or use medfinder.
• Generic substitution: All FDA-approved generic guanfacine ER formulations must demonstrate bioequivalence to brand Intuniv. If your patient's insurance allows generic substitution, pharmacies may be able to order a different manufacturer's generic.
• Mail-order pharmacy: Because guanfacine ER is not a controlled substance, it has no legal restrictions on mail-order dispensing. Consider writing a 90-day supply prescription to be filled via mail order to avoid future interruptions.
• Do not substitute IR for ER: Guanfacine immediate-release (Tenex) is not interchangeable with guanfacine ER (Intuniv) on a mg-for-mg basis. The ER formulation has significantly lower Cmax (60% lower), lower bioavailability (43% lower), and a delayed Tmax (3 hours later) compared to IR.

Switching to Clonidine ER: Clinical Considerations

If Intuniv is consistently unavailable, clonidine ER (Kapvay) is the most therapeutically similar alternative. Both are centrally acting alpha-2 adrenergic receptor agonists, but there are meaningful clinical differences:

• Clonidine ER is typically dosed twice daily; guanfacine ER is once daily
• Clonidine is more sedating due to less alpha-2A receptor selectivity
• There is no established dose equivalence between guanfacine ER and clonidine ER; initiate clonidine at a low dose and titrate
• Taper guanfacine before initiating clonidine to avoid cardiovascular effects from combined alpha-2 agonism

Drug Interactions to Keep in Mind

Key interactions relevant to clinical practice:

• Strong CYP3A4 inhibitors (ketoconazole, fluconazole, erythromycin): Increase guanfacine exposure. Limit dose to 2 mg/day while on inhibitor.
• Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin): Decrease guanfacine exposure by up to 70%. May need to increase guanfacine dose up to 8 mg/day while on inducer; reduce by 50% when inducer is discontinued.
• Valproic acid: Guanfacine ER increases valproic acid concentrations. Monitor for valproate toxicity in patients on combination therapy.
• CNS depressants and alcohol: Additive sedation; counsel families to minimize alcohol use and use caution with other sedating medications.

How medfinder Can Help Your Practice

Rather than sending patients and families on an unguided pharmacy search, consider directing them to medfinder's provider tools. medfinder contacts pharmacies near your patient to identify which ones currently have the medication in stock. Results are texted directly to the patient, reducing administrative burden on your staff and preventing treatment interruptions.

Bottom Line for Prescribers

Intuniv remains one of the more supply-stable options in ADHD management for 2026, but pharmacy-level stockouts are happening. The most critical clinical message is to proactively counsel patients not to stop abruptly, and to have a contingency plan before supply runs low. For a full provider guide on helping patients locate Intuniv, see How to Help Your Patients Find Intuniv. For clinical alternatives, see Alternatives to Intuniv.